Answers are grounded in this paper and cite their sources.
Cancer complexity arises not only from host genetics but also from interactions between the host and microbial communities. However, the field remains fragmented, and a systems‐level framework is needed to guide precision diagnostics and therapy. We develop the “oncobiome” as an integrative framework linking commensal, pathobiont, and tumor‐associated microbial activities to cancer development, progression, and treatment response. We describe how diet, antibiotics, therapy, and environmental factors may shape the shift from microbiome homeostasis to a malignancy‐associated oncobiome. An organ‐specific overview of the oncobiome illustrates how microbial communities interact with systemic microbial, immune, and metabolic networks. Mechanistically, we examine how microbial signals may influence the hallmarks of cancer, including genomic instability, altered tumor metabolism, and immune evasion, as well as epithelial barrier disruption, metastatic progression, and therapeutic resistance. Finally, we assess candidate microbial biomarkers for cancer detection, prognosis, and treatment‐response monitoring, alongside fecal microbiota transplantation, rationally designed microbial consortia, and selected probiotics. We distinguish preliminary anticancer findings from microbiota‐restoration and supportive‐care applications and highlight the need for prospective validation and contamination control. By integrating temporal microbial variation, anatomical niches, and cancer‐relevant functions, this review identifies priorities for development and clinical evaluation of microbiome‐based diagnostics and interventions.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: